PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma

BACKGROUND: The treatment for advanced primary hepatocellular carcinoma (HCC) is sorafenib (SORA), while HCC has become increasingly drug resistant with enhanced aerobic glycolysis. The present study aimed to examine the chemotherapeutic effects of a flavonoid proanthocyanidin B2 (PB2) on HCC. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jiao, Wu, Liwei, Ji, Jie, Chen, Kan, Yu, Qiang, Zhang, Jie, Chen, Jiaojiao, Mao, Yuqing, Wang, Fan, Dai, Weiqi, Xu, Ling, Wu, Jianye, Guo, Chuanyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525465/
https://www.ncbi.nlm.nih.gov/pubmed/31101057
http://dx.doi.org/10.1186/s13046-019-1194-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525465/
https://www.ncbi.nlm.nih.gov/pubmed/31101057
http://dx.doi.org/10.1186/s13046-019-1194-z

Ejemplares similares